is...busy operating two companies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LSD673, lol, I guess my point was,,,
I reach out and don't depend on my regular sources for information, as they have been exhausted. My post wasn't aimed at you.
DD
LSD, if you have time,,,
try these for starters
link: http://www.lagosmart.net/lagos/Hospitals.htm
DD
LSD673, there are many contacts out there,,,
I was simply giving an example of the response you will get if you try.
I see a lot of dd out here on this board,,,but the truth is out there, and depending on filings, news releases, court documents for DD is Not all there is, lol.. I know a lot of you good people put a lot of time on google, allafrica all the time, lol, and yahooooo.
you can find more information by contacting individuals. for instance, when Fox found this article about WHO demanding new trials, I looked at who wrote the darn thing. Many of you found my post and saw that the writer, etc, were sharlatans at best.
try this, type in Nigeria, clinics, google it. write to some of the people on the hospital staffs. Ask for directions to somebody in the know, lol.
I have very little free time, but I write an email, then I copy that email and paste it to a number of contacts.
surprising what one can learn.
Lsd, for you, I will write her back and ask. It took almost two weeks for her to respond to the first letter.
good hunting my friend!
DD
got a reply from Nigeria, maybe you will recognize the name of the respondent, lmao!
Yes. Nicosan is available in most pharmaceutical premises in Abuja. Please let me know where you stay and i will be able to tell you the exact outlets to go.
Thanks.
O.A.Salawu, Dr (Mrs)
DD wrote:
please, can you tell me if nicosan is still being produced and sold. where can I purchase nicosan?
DD
xechem management,,,
this explains the pps
DD
fox, who is that Santanna looking dude? em
DD
raven, that was my point,,,
this guy is all over the map, like many nigerians, lol.
weirdo! for sure!
DD
fox, look at just who wrote this! lmao!
weirdo!
Monday, April 21, 2008
Panel wants independent trial of herbal sickle cell drugs
By Chukwuma Muanya
By Chukwuma Muanya?????
link: http://www.yorubareligion.org/activiti/healing.html
DD
fox, kind of explains the recent drop in pps, huh?
well, so much for that. not good.
DD
EQ, makes me wonder about the supposed upcoming news,,,
will it be another drop on the base share price for Mr. B's group, maybe 0.0001 now? The way this is going down, just might be the news.
will it be news with production and sales numbers? with court cases now and maybe more looming, I kind of have doubts on that subject. although it has been a year without news, we may have to glean that information with intense DD. I would not doubt that we will learn more from court papers than with press releases.
IF I were a lawyer, advisor, attorney, I would not release anything until the legal matters are settled or my legal advisor determined it was in both plaintiff and defendant's best interest.
Although I expect news fairly soon, good or bad---or a mix of both, I do so only because the longer we go without news, the closer we are getting to reading it, lol.
I almost expect this to play out in this manner:
1. We get news about plant completion and possibly some production and sales numbers. we jump for joy.
2. We get an 8k saying Basu's group just got a sweetheart of a deal for waiting for months(rotflmao,,,poor guys). I mean come on, they are barely green! anger mngmnt course needed.
3. The stock will ralley, the monkey shakes the dust off, and everybody starts selling too early.lol
4. Longs are smiling, flippers are crying, shorts are jumping off of NY skyscrapers.
5 years from now,,,hmmmm?
DD
mrcsn, not bad, n200 and almost unlimited health care!
hmmm, wonder if Nicosan would be included in the HCHP plan?
maybe you should write them and ask.
DD
Fox, not sure I speak that language,,,
something about,,,something, lamo.
speakenzi engles?
DD
MM, niprd says niprisan has phase III completed,,,
what do you make of this?
DD
phase III,,,
National Institute for Pharmaceutical Research and Development (NIPRD) Health facility started in 1990 primarily to cater for the needs of staff and their dependants. It was headed then by Dr. (Mrs.) H.G. Khamofu, with Mrs. Christy Akpami as the nursing officer.' In 1994, the clinic began to participate in clinical research on sickle cell anaemia which brought on board four more doctors and two (2) nurses added to the staff strength namely Dr. Margaret Ekpenyong; Dr. Victoria Eyo, Dr. B. S. Audu, Dr. Akolo; Mrs. Rose Jiya and Mrs. Adline Osuji as well as a nutritionist/counsellor Mrs. O. Samuel and research activities then increased rapidly.
Dr. (Mrs.) Khamofu and Dr. (Mrs.) Margaret Ekpenyong coordinated Sickle Cell Anaemia research on which largely entailed the conduct of clinical trials on anti-sickling phytomedicine. This anti-sickling phytomedicine - NIPRISAN - made it through all the phases I-III stages of clinical trials and was found to be useful in the management of sickle cell anaemia. While Dr. Victoria Eyo pioneered and coordinated HIV / AIDS clinical research activities. HIV AIDS clinical trial was initially limited to herbal medicine. Discovery then was that these herbal medicine were found to have immune boosting capacity but no viricidal effects. This project however became the basis for National Institute for. Pharmaceutical Research and Development (NIPRD) being mandated to co-ordinate a Nation wide Verification exercise for herbal medicines useful in HIV/AIDS treatment in 2001.
This anti-sickling phytomedicine - NIPRISAN - made it through all the phases I-III stages of clinical trials and was found to be useful in the management of sickle cell anaemia.
interesting, straight from NIPRD
link: http://niprdng.org/clinicdepart.htm
DD
ACHIEVEMENTS
a. Formulations have been developed for the following plant extracts which have been studied in the Institute.
A solid dosage form of NIPRISAN, a preparation for the Management of Sickle Cell disease.
A solid dosage form of CONAVIL, a preparation for use in the supportive Management of HIV/AIDS.
A solid dosage form of NIPRD AM-1, a preparation for the treatment of uncomplicated malaria.
A semi solid topical preparation of NIPRISAN for the treatment of fungal infections.
A solid dosage form of a plant extract for the management of peptic ulcer.
b. Development of raw materials
Developed pharmaceutical grade starch at the lab stage.
Developed cellulose for use as excipient from various sources at lab stage.
Prepared a feasibility report on the grade starch from cassava
c. Formulation studies
Compaction studies on herbal medicines
Deformation characteristics of starches
Determination of effect of herbal activities/ulcer on the deformation characteristics of excipients.
ON-GOING STUDIES
Further studies on
Anti-malaria herbal formulation (AM1)
Immunobooster drug (CONAVIL)
Antifungal herbal drug (NIPRISAN)
Survey of incidence side effect in some patients on HAART in relation to age, sex, ethnic group, social behavior, concurrent drug use, nutrition and initial CD4 count
Evaluation of the sustained released properties of some hydrocolloids from indigenous plants
Stability studies on some ARVs (planning stage)
AREAS OF COMPETENCE
Formulation science
Quality control of dosage forms of drugs
Stability studies on drugs
Development of pharmaceutical excipients
RESEARCH FELLOWS
1. O.O. Kunle, Ph.D
Deputy Director/ Principal Research Fellow
2. B. Kabele-Toge, Ph.D
Senior Research Fellow
3. C.Y.Isimi, Ph.D
Senior Research Fellow
4. D.A.N. Oqua, Ph.D
Senior Research Fellow
5. P.F. Builders, M.Pharm
Research fellow II
6. F. Ohwoavworhua,
M.Pharm
Research Fellow II
7. M.O. Emeje, M.Pharm
Research Fellow II
8. A. Egieyeh, B. Pharm.
Research Fellow II
TECHNICAL STAFF
1. Mrs Abigael Nnarum
Technologist I
2. Abuh A. Garuba
Technologist I
3. Mrs. Rosemary Akuboh
Asst. Technologist
link: http://niprdng.org/ptandrmddepart2.htm
DD
article that mentions nicosan,,,
http://article.wn.com/view/2008/01/18/Sufferers_of_Sicklecell_anemia_go_through_awful_pain/?template=cheetah-search-adv%2Findex.txt
Sickle-cell anemia (SS) is unfortunately one of the serious and most awful diseases in the world. And the most disgusting a sufferer comes across is pain, pain in several places at the same time.
Sufferers of Sickle-cell anemia go through awful pain
BREAKING NEWS
World after 9/11 attacks: War on terror or US propaganda?
Number of homeless families in USA continues to increase
War on Iran: Unleashing Armageddon in the Middle East
Chinese army demonstrates its skills
More...
It’s a group of genetic disorders caused by sickle hemoglobin (Hgb S or Hb S). In many forms of the disease, the red blood cells change shape upon deoxygenation because of polymerization of the abnormal sickle hemoglobin; the hemoglobin proteins stick to each other, causing the cell to get a rigid surface and sickle shape. This process damages the red blood cell membrane, and can cause the cells to become stuck in blood vessels. This deprives the downstream tissues of oxygen and causes ischemia and infarction, which may cause organ damage, such as stroke.
The disease is chronic and lifelong. Individuals are most often well, but their lives are punctuated by periodic painful attacks. Life-expectancy is shortened, but contemporary survival data is lacking. Older studies indicated that sufferers could live to an average of 40 to 50 years, with the average age for males being 42 and the average age for females being 48. Sickle-cell disease occurs more commonly in people (or their descendants) from parts of the world such as sub-Saharan Africa, where malaria is or was common, but it also occurs in people of other ethnicities. This is because those with one or two alleles of the sickle cell disease are resistant to malaria since the red blood cells are not conducive to the parasites - in areas where malaria is common there is a survival value in carrying the sickle cell genes. The mutated allele has incomplete dominance, which means that an individual who carries the sickle cell genes but does not have the disease still retains immunity to malaria.
Patients with sickle-cell anemia can have symptoms that vary in severity.
The most terrible is a vaso-occlusive crisis (otherwise known as painful crisis) caused by sickle-shaped red blood cells that obstruct capillaries and restrict blood flow to an organ, resulting in ischemia, pain, and organ damage. The frequency, severity, and duration of these crises vary tremendously.
Because of its narrow vessels and function in clearing defective red blood cells, the spleen is frequently affected. It is usually infarcted before the end of childhood in individuals suffering from sickle-cell anemia.
Bones, especially weight-bearing bones, are also a common target of vaso-occlusive damage. This is due to bone ischemia.
Various approaches are being sought for preventing sickling episodes as well as for the complications of sickle-cell disease. Other ways to modify Hb switching are being investigated, including the use of phytochemicals such as Nicosan.
DD
texas, I really have no idea,,,
but the longer we go without news, the sooner we should have news,
DDareDDevil
clrmng, just waiting around,,,
I found that one peice on production and thought I would post it,
DDareDDevil
clrmng, no,,,
do you think I am?,,,
LMAO!
wow, great pic, wazzup my old friend.
DDareDDevil
Legion, this was the latest production numbers I could find, however, This would be good news if in fact it WERE true.
Time will tell, and we will see just how trustworthy the new management is.
They say, no news is good news,,,I beg to differ.
DDareDDevil
fox my man, that's what I get,,,
was just asking, lmao!
DDareDDevil
The 50k I posted comes from an article from feb 25th of this year.
link: http://allafrica.com/stories/200802250547.html
DDareDDevil
Another study on sickle cell treatments,,,
involves a fruit called Carao,
There is also an ongoing study by Dr. Attahiru I. Sokoto in Nigeria, a pediatrician
who calls carao a "new dawn in the management of Sickle Cell Disease and Anaemia."
CR Natural makes regular donations of carao to his hospital.
link: http://www.anemiaanswer.com/?gclid=CKjBpfv0-5ICFQQqlgodvmIXGg
Dr. Attahiru I. Sokoto
Specialist Hospital Sokoto,Nigeria
Organization type: Research and/or academic institution
Email: drsokoto@yahoo.com
Nutrition, sickle cell disease, infectious disease, HIV in children, Malaria
Source of Funding: Government
Country: Nigeria
Address: Specialist Hospital Sokoto, P.M.Box 2133,Sokoto State,Nigeria
Contact: Dr.Attahiru Isa Sokoto
Phone: +234-80-52613602
Online Community
Professional Directory
link: http://www.chnri.org/content/organization/detail/747/
I have e-mailed them both and am awaiting response.
I asked if they have heard "anything", reguarding xechem,lol
DDareDDevil
lmf, thanks, eom
DDareDDevil
50,000 capsules per day, at last count,,,
is this correct?
Chris Agabi
Abuja
At least four million Nigerians are suffering from sickle cell anemia and about 80 per cent of Nigerian children born with the disease die before the age of five, representing the worst case in the world.
Speaking during the visit of the Minister of State for Science and Technology, Dr. Alhassan B. Zaku, to the Sheda Science and Technology Complex (SHESTCO) in Abuja, the Managing Director, XECHEM Pharmaceuticals Nigeria Limited, Mr. Ireti Oniyide, said NICOSAN, a drug by XECHEM, was not a complete cure for the disease but it has a high success ratio to effectively manage it.
Currently, he said XECHEM, located in the technology village, produces 50,000 capsules of the drug daily which will likely increase to one million.
He said the economic benefits of the drugs was really enormous, adding that local farmer's need to farm sorghum which is the primary raw material.
He said the products are being marketed in Dubai and the United States.
The minister praised the efforts of the company and urged them to make cheaper drugs.
Meanwhile, the minister has called on the private sector to partner with government on mass producing local inventions for commercial benefits.
Relevant Links
West Africa
Health and Medicine
Nigeria
"Our problem is linking our research with industries. We have to have a public private partnership. Our job is to research and develop while the private sector should produce and sell. We hope individuals will come here and work with us."
He noted that government "spends so much money on research and development which the private sector has to complement by commercialising the inventions for the benefit of Nigerians."
The minister also expressed concern over the situation where several government departments develop similar technologies and research on similar products, saying that a committee has been set up to coordinate all the various government research institutions to collaborate on researches to aviod duplications.
DDareDDevil
XKEM INSIDERS ON BOARD OF DIRECTORS*
names of people that DO know what is going on.
Name (Connections) Board Relationships Title Age
Robert Swift 32 Relationships Chairman, Interim Chief Executive Officer, Interim President and Chief Oversight Officer --
Ramesh Pandey M.sc. Ph.d. D.d.g. Faic 33 Relationships Founder, Director, Member of Nominating Committee and Member of Stock Option Committee 69
William Pursley 32 Relationships Chairman of Ceptor and Chief Executive Officer of Ceptor 53
Stephen Burg 34 Relationships Assistant Secretary, Director, Member of Stock Option Committee, Member of Audit Committee, Member of Compensation Committee and Member of Nominating Committee 69
Renuka Misra Ph.D. 32 Relationships Member of the Scientific Advisory Board and Director of Natural Products Research & Development --
Other Board Members on Board of Directors*
Name (Connections) Board Relationships Primary Company Age
C. Propst Ph.D. 32 Relationships Xechem International Inc. --
Otto Plescia Ph.D. 32 Relationships Xechem International Inc. --
Lester Mitscher Ph.D. 111 Relationships Xechem International Inc. --
Zhang Li-He Ph.D. 32 Relationships Xechem International Inc. --
Allen Laskin Ph.D. 32 Relationships Xechem International Inc. --
Sun Han-Dong Ph.D. 32 Relationships Xechem International Inc. --
Sukh Dev Ph.D., D.Sc., F.N.A. 39 Relationships Gujarat Alkalies & Chemicals Ltd. 83
Geoffrey Cordell Ph.D. 32 Relationships Xechem International Inc. --
William Bradner Ph.D. 32 Relationships Xechem International Inc. --
Joan Bennett Ph.D. 32 Relationships Xechem International Inc. --
Federico Arcamone Ph.D. 32 Relationships Xechem International Inc. --
Brian Arenare M.D. 32 Relationships Xechem International Inc. --
Elias Anaissie M.D. 32 Relationships Xechem International Inc. --
Nitya Anand Ph.D., F.N.A. 32 Relationships Xechem International Inc. --
Marcy Street 32 Relationships Xechem International Inc. --
Dakota Pippins 32 Relationships Xechem International Inc. --
Tamara New 32 Relationships Xechem International Inc. --
Stephen Kolison 32 Relationships Xechem International Inc. --
Kofi Lomotey 32 Relationships Xechem International Inc. --
Wallye Holloway 32 Relationships Xechem International Inc. --
Nadine Hack 32 Relationships Xechem International Inc. --
Marcellus Grace 32 Relationships Xechem International Inc. --
Glenda Glover 32 Relationships Xechem International Inc. --
Desiree Delgado 32 Relationships Xechem International Inc. --
Vincent Carter 32 Relationships Xechem International Inc. --
George Fraser 32 Relationships Xechem International Inc. --
J. Henry III 32 Relationships Xechem International Inc. --
Martin Biggs 32 Relationships Xechem International Inc. --
tried calling any?
don't EVEN get me started on their relationships to each other! I could write a book, lol.
instead of Biggs, Swift, Basu, etc, maybe you should try fixating on another from this list of real "insiders".
DDareDDevil
ooops!,,,
DD
fox, i saw your post and completely agree with you.
DD
lsd673, this is indeed old information,,,
I asked about this almost two years ago and was informed that this was shelved so that they could concentrate on Niprisan/ Nicosan/HMF-5.
They also were supposed to be involved in the production and sales of vitamin c in conjunction with the research facility in Nigeria, SHESTCO, due to the concentrated form of vitamin c in some of the local plants.
unfortunately, this is going nowhere, even though you can look up gugulon and find it.
Of course, I haven't looked for any filings, so this is imo.
DDareDDevil
DDog, have you seen this before?,,
link: www.cbd.int/doc/meetings/abs/abswg-06/information/abswg-06-inf-04-rev1-en.doc
For example, traditional knowledge is not widely used in the pharmaceutical industry today (Petersen, 2007), but traditional knowledge is used to guide research in some smaller discovery programs, and efforts have been made to develop ABS agreements around its use. For example, in Nigeria an MOU was developed for a research collaboration between the National Institute for Pharmaceutical Research and Development (NIPRD) and a traditional health practitioner, Rev. Ogunyale, focused on indigenous medical knowledge about sickle cell disorder, and indigenous biodiversity. The collaboration began in 1992, and there existed little guidance on how to structure such an agreement, but an innovative process for reaching mutually agreed terms, signing an MOU, and sharing benefits was developed. XECHEM International was granted a license to the resulting product, in return for providing 7.5% of gross sales as royalties. A shortfall of the arrangement continues to be the lack of sharing financial and other benefits paid by XECHEM to NIPRD with individual NIPRD researchers, and Rev. Ogunyale’s Foundation and his community. There are also concerns about the benefit-sharing package as a whole, resulting in part from a lack of involvement of researchers and Rev. Ogunyale in negotiations for the License Agreement (Wambebe, 2007).
DDog, sorry, was stuck looking for the link and my time expired, lol
DD
found some PCAOB information about xechem,,,
found this, not significant, but here is the link,
http://www.pcaobus.org/Support_Fees/Issuers_Paid.pdf
and some political contribution,
DD
drifter, i can just feel the angst you are going through!!
like i said a year ago, this stock will make one a shitzo!
David Blech needs to share his Lithium!!!!
should be our new motto,,,,GOT LITHIUM??
rotflmao
DD
p.s. i am not worried about your money, lol
fiat, don't worry about it, lol, em
DD
hey LT, same here, it is one of those stocks you get into and end up knowing wayyyy too much, lol
still, you are right, just hang in, something is gonna pop.
DDareDDevil
why was my post about an investor of xechem, geduld removed? this was and is pertinent information regaurding institutional investing in our stock.
are we not allowed to post this information concerning xechem??
DDareDDevil
clrnmg, that means that the institutional investor is reporting it's holdings, in this case, from last quarter, filed dec 31st
Institutional Investment Manager Filing this Report:
Name: Platinum Management (NY) LLC
Address: 152 West 57th Street, 54th Floor
New York, NY 10019
DDareDDevil
clrnmg,,,
no private mail, but the answer is that it is debt security, usually maturing in one to 10 years.
good luck man!
DDareDDevil
hey fox, you guys have seen this?
seems ceptor is still around:
Acquisition by Xechem International, Inc. and application of push-down accounting - - - - - - 4,118,463 - - 915,846 5,034,309
Option granted pursuant to spinoff agreement - - - - - - 2,082,500 - - - 2,082,500
Common stock subject to repurchase under put right - - (401,305 ) (40 ) - - (1,637,285 ) - - - (1,637,325 )
Common stock issued May 2004, in connection with bridge loans ($1.22) - - 451,597 45 - - 549,955 - - - 550,000
Common stock issued May 2004, to placement agent for bridge loans ($2.50) - - 36,000 4 - - 89,996 - - - 90,000
Common stock issued September 2004, net of offering expenses of $70,760 ($1.68) - - 554,413 55 - - 929,176 - - - 929,231
Common stock issued December 2004 to advisors for past services ($2.50) - - 675,690 68 - - 1,689,157 - - - 1,689,225
Reclassification in December 2004 of advances from Xechem as contribution to capital - - - - - - 350,310 - - - 350,310
Minority shareholders pursuant to recapitalization - - 1,850,000 185 - - (185 ) - - - -
Common stock issued December 2004 pursuant to exercise of options granted pursuant to spinoff agreement ($0.00001) - - 3,031,943 303 (303 ) - - - - - -
Intrinsic value of beneficial conversion feature of replacement notes - - - - - - 1,111,240 - - - 1,111,240
Common stock issued December 2004 in conversion of convertible note ($1.25) - - 167,610 17 - - 209,495 - - - 209,512
Common stock issued December 2004 in connection with litigation settlement ($2.50) - - 125,000 12 - - 312,488 - - - 312,500
Capital contributed by Xechem International, Inc. - - 350,310
CepTor Agreement, dated March 31, 2004 (the ``CepTor Agreement"), by and among William Pursley, Xechem and the Company (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K, dated December 9, 2004 (the "2004 Form 8-K"))
4 .3 First Amendment to CepTor Agreement effective April 23, 2004, by and among William Pursley, the Company and Xechem (incorporated herein by reference to Exhibit 4.2 to the 2004 8-K)
4 .4 Second Amendment to CepTor Agreement, dated December 9, 2004, by and among William Pursley, the Company and Xechem (incorporated by reference to Exhibit 4.3 to the 2004 8-K)
4 .5 Form of Unit Warrant (incorporated by reference to Exhibit 4.4 to the Company's Registration Statement on Form SB-2 as filed with the SEC on February 11, 2005 (the "Form SB-2"))
4 .6 Form of Amended and Restated Convertible Promissory Note (incorporated herein by reference to Exhibit 4.7 to the 2004 10-KSB)
4 .7 Form of Subscription Agreement (incorporated herein by reference to Exhibit 4.6 to the Form SB-2)
4 .8 Securities Purchase Agreement, dated June 17, 2005 by and between the Company, Xechem and William Pursley (incorporated herein by reference to Exhibit 99.01 to the Company's Current Report on Form 8-K filed on June 20, 2005)
DDareDDevil
clrmng, because it shows large investors still have us on radar,
yes, it is not a big stake by any means, however, it also signifies that there are still large investors willing to place a bet that x will succeed.
if you search hard enough, you will see that this is the first investments since before the end of the year( 11-14 ) by these types of investors.
somebody is hearing something.
DDareDDevil
ps, these were made on 2-14 and 2-15